# EDGAR Filing Document

**Accession Number:** 0001227636
**File Stem:** 0000921895-26-000850
**Filing Date:** 2026-3
**Character Count:** 10289
**Document Hash:** 079c8dcd0234fc12df6d97553440aeda
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000921895-26-000850.hdr.sgml**: 20260331

**ACCESSION NUMBER**: 0000921895-26-000850

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260331

**DATE AS OF CHANGE**: 20260331

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neuronetics, Inc.
- **CENTRAL INDEX KEY:** 0001227636
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90797
- **FILM NUMBER:** 26821631

**BUSINESS ADDRESS:**
- **STREET 1:** 3222 PHOENIXVILLE PIKE
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 877-600-7555

**MAIL ADDRESS:**
- **STREET 1:** 3222 PHOENIXVILLE PIKE
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEURONETICS INC
- **DATE OF NAME CHANGE:** 20030416
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chernett Jorey
- **CENTRAL INDEX KEY:** 0002042077

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 6222 INDIANWOOD TR.
- **CITY:** BLOOMFIELD HILLS
- **STATE:** MI
- **ZIP:** 48301

## Ex-1

Exhibit 1

**<u>Transactions in the Securities of the Issuer in the Past 60 Days</u>**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; Shares of Common Stock<br> <u>Purchased/(Sold)</u> | &nbsp;&nbsp; Price Per<br> <u>Share ($)<sup>1</sup></u> | &nbsp;&nbsp; Date of<br> <u>Purchase / Sale</u> |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;19000 | &nbsp;&nbsp;$1.54 | &nbsp;&nbsp;2/4/2026 |
| &nbsp;&nbsp;(10000) | &nbsp;&nbsp;$2.06 | &nbsp;&nbsp;2/10/2026 |
| &nbsp;&nbsp;(90627) | &nbsp;&nbsp;$2.04 | &nbsp;&nbsp;2/11/2026 |
| &nbsp;&nbsp;50000 | &nbsp;&nbsp;$1.32 | &nbsp;&nbsp;2/19/2026 |
| &nbsp;&nbsp;40000 | &nbsp;&nbsp;$1.29 | &nbsp;&nbsp;2/20/2026 |
| &nbsp;&nbsp;531000 | &nbsp;&nbsp;$1.16 | &nbsp;&nbsp;3/17/2026 |
| &nbsp;&nbsp;607400 | &nbsp;&nbsp;$1.35 | &nbsp;&nbsp;3/18/2026 |
| &nbsp;&nbsp;450000 | &nbsp;&nbsp;$1.33 | &nbsp;&nbsp;3/19/2026 |
| &nbsp;&nbsp;169472 | &nbsp;&nbsp;$1.41 | &nbsp;&nbsp;3/20/2026 |
| &nbsp;&nbsp;125000 | &nbsp;&nbsp;$1.40 | &nbsp;&nbsp;3/25/2026 |
| &nbsp;&nbsp;25000 | &nbsp;&nbsp;$1.44 | &nbsp;&nbsp;3/26/2026 |
| &nbsp;&nbsp;500000 | &nbsp;&nbsp;$1.35 | &nbsp;&nbsp;3/27/2026 |
| &nbsp;&nbsp;385442 | &nbsp;&nbsp;$1.25 | &nbsp;&nbsp;3/30/2026 |

---

<sup>1</sup> The prices reported in this column are weighted average prices. The Reporting Person undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased (or sold) at each separate price such shares were purchased.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Neuronetics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.01 par value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Jorey Chernett**<br>6222 Indianwood Tr.<br>Bloomfield Hills MI 48301<br>(248) 469-8811

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/31/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Chernett Jorey** | Name of reporting person<br>**Chernett Jorey** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**9778718.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**9778718.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9778718.00** | Aggregate amount beneficially owned by each reporting person<br>**9778718.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**14.12%** | Percent of class represented by amount in Row (11)<br>**14.12%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.01 par value

**(b) Name of Issuer:**
Neuronetics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3222 PHOENIXVILLE PIKE, MALVERN, PA, 19355

This Schedule 13D (this "Schedule 13D") is filed by the Reporting Person (as defined below) with respect to the Common Stock, $0.01 par value (the "Shares"), of Neuronetics, Inc, a Delaware corporation (the "Issuer").

The Reporting Person previously reported beneficial ownership of shares of the Issuer described herein on Schedule 13G, initially filed on November 24, 2025 (as amended, the "Schedule 13G"). This Schedule 13D represents the initial statement on Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission with respect to shares of the Issuer and amends and supersedes the Schedule 13G.

**Item 4. Purpose of Transaction**

The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to further increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable.

The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Issuer's Board of Directors, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate percentage of Shares beneficially owned by the Reporting Person is based upon 69,276,593 Shares outstanding as of March 10, 2026, as disclosed in the Issuer's Registration Statement on Form S-3, filed with the U.S. Securities and Exchange Commission (the "SEC") on March 17, 2026.

As of the close of business on March 31, 2026, the Reporting Person beneficially owned 9,778,718 Shares.

Percentage: Approximately 14.12%

**(b)**
1. Sole power to vote or direct vote: 9,778,718
2. Shared power to vote or direct vote: 0
3. Sole power to dispose or direct the disposition: 9,778,718
4. Shared power to dispose or direct the disposition: 0

**(c)**
The transactions in the Shares by the Reporting Person during the past sixty days are set forth in more detail in Item 6.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Other than as escribed herein, the Reporting Person does not have any other contracts, arrangements, understandings or relationships with respect to the Issuer's securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Chernett Jorey

**Signature:** /s/ Jorey Chernett

**Name/Title:** Jorey Chernett

**Date:** 03/31/2026